AVDL Insider Trading
Insider Ownership Percentage: 4.80%
Insider Buying (Last 12 Months): $526,363.04
Insider Selling (Last 12 Months): $0.00
Avadel Pharmaceuticals Insider Trading History Chart
This chart shows the insider buying and selling history at Avadel Pharmaceuticals by year and by quarter.
Skip ChartChart Data in Insider Trading History Table
Avadel Pharmaceuticals Share Price & Price History
Current Price: $8.53
Price Change: ▼ Price Decrease of -0.04 (-0.47%)
As of 03/24/2025 05:00 PM ET
Avadel Pharmaceuticals Insider Trading History
Avadel Pharmaceuticals Institutional Trading History
Data available starting January 2016
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Read More on Avadel Pharmaceuticals
Volume
658,405 shs
Average Volume
1,184,163 shs
Market Capitalization
$824.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.57
Who are the company insiders with the largest holdings of Avadel Pharmaceuticals?
Who are the major institutional investors of Avadel Pharmaceuticals?
Which major investors are selling Avadel Pharmaceuticals stock?
Within the last quarter, AVDL stock was sold by these institutional investors:
- Vestal Point Capital LP
- Woodline Partners LP
- Polar Capital Holdings Plc
- Bank of America Corp DE
- New York State Common Retirement Fund
- Nomura Holdings Inc.
- Group One Trading LLC
- Barclays PLC
Which major investors are buying Avadel Pharmaceuticals stock?
During the last quarter, AVDL stock was acquired by institutional investors including:
- Two Seas Capital LP
- Two Seas Capital LP
- Brandes Investment Partners LP
- Janus Henderson Group PLC
- Braidwell LP
- Kennedy Capital Management LLC
- Renaissance Technologies LLC
- Knott David M Jr
Within the last year, these company insiders have bought Avadel Pharmaceuticals stock:
- Gregory J Divis (CEO)
- Peter J Thornton (Director)
- Thomas S Mchugh (CFO)
- Geoffrey Michael Glass (Director)
- Linda Palczuk (Director)
Learn More investors buying Avadel Pharmaceuticals stock.